Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
brain cancer
Pharma
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.
Angus Liu
Aug 6, 2024 5:25pm
Day One pressures Novartis with FDA nod for novel RAF inhibitor
Apr 23, 2024 10:13pm
Deal tees up delivery of oncolytic viruses to brain using robots
Dec 21, 2021 8:40am
Ultrasound unlocks blood-brain barrier in cancer clinical trial
Sep 14, 2021 9:00am
Microrobots cross blood-brain barrier with anti-cancer payload
Mar 30, 2021 8:30am
Bayer's Stivarga on the hunt for rare glioblastoma OK
Jun 20, 2019 11:12am
